All In Biotech

Drug Trial Radar · NCT00003759

AD 32 With or Without BCG After Surgery in Treating Patients With Newly Diagnosed or Recurrent Superficial Bladder Cancer

Intravesical Treatment of Superficial Bladder Cancer Characterized on the Basis of the Tumor Markers p53 and pRb

Last checked: Nov 20, 2026Latest source record: Jan 31, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

Not stated

Start

Nov 1998

Primary completion

Not stated

Study completion Nov 2002

Sponsor

Lead sponsor
Anthra PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Jul 18, 2003

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Biological therapies such as BCG use different ways to stimulate the immune system and stop cancer cells from growing. It is not yet known whether AD 32 is more effective with or without BCG after surgery for superficial bladder cancer. PURPOSE: Randomized phase II trial to compare the effectiveness of AD 32 with or without BCG after surgery in treating patients who have newly diagnosed or recurrent superficial bladder cancer.

Conditions

  • Bladder Cancer

Interventions

  • BCG vaccineBiological

  • valrubicinDrug

  • conventional surgeryProcedure

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Texas - MD Anderson Cancer Center

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.